Shots:

• Roivant’s launched new subsidiary, Hemavant, that entered into a licensing agreement with Eisai for exclusive global rights to RVT-2001 for the treatment of transfusion-dependent anaemia in patients with lower-risk myelodysplastic syndromes
• Hemavant plans to develop RVT-2001 as an oral therapy with expected P-I/II study initiation in H1’22 with initial data expected in 2023
• RVT-2001 showed RBC-TI rate of >30% in a P-I/II trial involving a subset of 19 patients with lower-risk, transfusion-dependent MDS, 15 out of 19 had prior treatment with BMS’ Revlimid (lenalidomide) and/or hypomethylating agents

 Ref: Roivant | Image: Fierce Biotech